Screening Methods to Discover the FDA-Approved Cancer Drug Encorafenib as Optimally Selective for Metallothionein Gene Loss Ovarian Cancer.

ABSTRACT:

Background/objectives

All 11 metallothionein protein-coding genes are located on human chromosome 16q13. It is unique among human genetics to have an entire pathway's genes clustered in a short chromosomal region. Since solid tumors, particularly high-grade serous ovarian cancer (HGSC), exhibit high rates of monoallelic aneuploidy, this region is commonly lost. Studies have not yet been performed to determine what vulnerability may be created in cancer cells with low metallothionein expression. Here, a screen of FDA-approved cancer small molecule drugs for those best targeting low metallothionein ovarian cancer was completed.

Methods

Screening methods were tested and compared using vehicle-treated negative controls and cadmium chloride, a positive control for cell loss selec

SUBMITTER: Rees A 

PROVIDER: S-EPMC11764637 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature